Brisbane, Australia; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Fitzroy, Australia; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Innsbruck, Austria; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Vienna, Austria; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Campinas, Brazil; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Ribeirăo Preto, Brazil; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Salvador, Brazil; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Santo Andre, Brazil; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Sao Paulo, Brazil; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Pleven, Bulgaria; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Plovdiv, Bulgaria; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Sofia, Bulgaria; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Sofia, Bulgaria; Research Site:
SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).
Stara Zagora, Bulgaria; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Varna, Bulgaria; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Beijing, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV).
Beijing, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Beijing, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
Beijing, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Chongqing, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
Guangzhou, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Guangzhou, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV).
Guangzhou, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
Hangzhou, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
Hangzhou, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Hong Kong, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Hong Kong, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Hong Kong, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
Hunan, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Jinan, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
Shanghai, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Shanghai, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).
Shanghai, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV).
Shanghai, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Xi'An, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Zhengzhou, China; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.
Tallinn, Estonia; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
Tartu, Estonia; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
Bondy, France; Research Site:
A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.
Clermont-Ferrand, France; Research Site:
A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.
Clichy, France; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Creteil, France; Research Site:
A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.
Montpellier, France; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Nice, France; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Orleans, France; Research Site:
A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.
Paris, France; Research Site:
A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.
Saint Laurent Du Var, France; Research Site:
A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.
Strasbourg, France; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Toulouse, France; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Villejuif, France; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Berlin, Germany; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Essen, Germany; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Frankfurt Am Main, Germany; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Freiburg, Germany; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Homburg, Germany; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Köln, Germany; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Oberhausen, Germany; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Aigaleo - Attiki, Greece; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)
Alexandroupolis, Greece; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)
Athens, Greece; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Athens, Greece; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)
Patras, Greece; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)
Piraeus, Greece; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)
Thessaloniki, Greece; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Thessaloniki, Greece; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)
Augusta, Italy; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Bari, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Bologna, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253
Bologna, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Brescia, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253
Brescia, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Cagliari, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Caserta, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Castellana Grotte, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Catania, Italy; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Galatina, Italy; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Messina, Italy; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Messina, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Milano, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253
Milano, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Napoli, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Padova, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Palermo, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Palermo, Italy; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Parma, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Parma, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253
Pisa, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Reggio Emilia, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253
Reggio Emilia, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
San Giovanni Rotondo, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Torino, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Trieste, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Udine, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Verona, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Seoul, Korea, Republic of; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Riga, Latvia; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
Kaunas, Lithuania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
Klaipeda, Lithuania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
Vilnius, Lithuania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).
Rotterdam, Netherlands; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Auckland, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Auckland, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Christchurch, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Hamilton, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Hamilton, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
New Plymouth, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Rotorua, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Whangarei, New Zealand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Bialystok, Poland; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Bydgoszcz, Poland; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Krakow, Poland; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Poznan, Poland; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Wroclaw, Poland; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Bucharest, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)
Cluj-Napoca, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)
Constanta, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)
Iasi, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)
Timisoara, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)
Chelyabinsk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Ekaterinburg, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Irkutsk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Kazan, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Krasnoyarsk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Moscow, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Nizhny Novgorod, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Novokuznetsk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Novosibirsk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Rostov-Na-Donu, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Samara, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Samara, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Smolensk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
St Petersburg, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
St Petersburg, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Stavropol, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Stavropol, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Tomsk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Tumen, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Ufa, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Volgograd, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Yakutsk, Russian Federation; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Singapore, Singapore; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Kaohsiung, Taiwan; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Kueishan, Taiwan; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Taipei, Taiwan; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Bangkok, Thailand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Chiang Mai, Thailand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Khon Kaen, Thailand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Songkhla, Thailand; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Ankara, Turkey; Research Site:
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B
Ankara, Turkey; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
Ankara, Turkey; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Antalya, Turkey; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
Ege, Turkey; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Gaziantep, Turkey; Research Site:
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B
Istanbul, Turkey; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
Istanbul, Turkey; Research Site:
A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection
Izmir, Turkey; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
